Pfizer Inc. (NYSE: PFE) is scheduled to provide its full-year 2026 financial guidance on Tuesday, with Bank of America Securities expecting the company's growth profile to closely resemble conditions ...
Pfizer is a Buy for medium- to long-term investors, trading at a low P/E and undervalued versus peers, with strong non-COVID growth. Strategic pivots include aggressive R&D, cost-cutting, and the ...
Pfizer is one of the world's largest and oldest drug companies. Thanks to its Covid vaccine, shares rose dramatically during the pandemic. Now that the stock has sharply corrected, long-term investors ...
Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...
Pfizer Inc. provided early 2025 and 2026 guidance, projecting flat-to-declining revenues and EPS, highlighting persistent growth and profitability challenges. Pfizer faces major patent expiries, ...
Pfizer now trades well below its pandemic-era multiples, with its valuation anchored to what the business earns today — not what it earned in 2021. The stock yields over 6%, one of the highest payouts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback